Cat joins CHASE as Head of Insights after having 16 years’ experience in the life-sciences industry. She started in medical communications, working with global pharmaceutical teams to deliver creative and impactful education programmes for patients and healthcare professionals. Cat then moved into global marketing leadership roles at a transformative time for Ashfield and STEM Healthcare. Cat brings an excellent understanding of what clients want and building the right tailored solutions.
Her role at CHASE is to gather insights from healthcare professionals, industry, and CHASE activities to uncover more ways to help patients access the treatment they need.
Graham Hawthorn, Managing Director of CHASE said:
“We’re delighted that Cat has joined the CHASE team in the newly created Head of Insights role. Insight led decision making, that’s in tune with NHS and patient needs, has never been more important for the pharma and healthcare sectors and we’re committed to playing our part. Welcome Cat!”
Explore our latest thinking, event updates and industry insights to stay informed.
Kent and Medway has signed the first local variation of the PCN DES, worth £10 million a year. CHASE assesses what the framework still leaves unsettled.
From April 2027, NHS Carbon Reduction Plan rules demand full scope 3 emissions data. CHASE assesses what this means for pharma and medtech suppliers.
Yvette Cooper is the UK's new health secretary after a reshuffle that also reshaped the medtech brief. Here's what it means for pharma, medtech and NHS teams.
.svg)
